



Media release – for immediate dissemination

Clearbridge BioMedics makes a big impact at the 2012 Asian Innovation Awards

21 November 2012, Singapore – Clearbridge BioMedics won the top three awards at Asian Innovation Awards 2012, which were announced yesterday evening in Hong Kong. Clearbridge BioMedics took the grand prize for **The Asian Innovation Awards 2012**, which recognises innovations that break conventional processes to improve quality of life or productivity. Clearbridge BioMedics also received the **Credit Suisse Technopreneur of the Year Award**, which honors the entry that best applies technology with the greatest potential for commercial success. The Company proved to be well-liked amongst the guests at the event, and also claimed the **Audience Choice Award**. Clearbridge BioMedics beat 11 other finalists who were vying for these awards and who had been short-listed from more than 240 applications. The Asian Innovation Awards 2012 were presented by The Wall Street Journal in partnership with Credit Suisse.

"Innovation and entrepreneurship play essential roles in driving economic growth across the Asia-Pacific region," said Dan Molloy, global executive director for multi-media sales, Asia, for The Wall Street Journal. "The Wall Street Journal is pleased to continue to recognize some of Asia's most creative business ideas and to celebrate the region's newest technological advances and innovations. My congratulations to Clearbridge BioMedics on their ingenuity and success in this year's Asian Innovation Awards."

"Clearbridge BioMedics is absolutely delighted and honored to win, not one but three awards, at the Asian Innovation Awards. This fantastic win is a nice validation of our work, and for the need to find better ways to diagnose, treat and conduct research on cancer. We aim to further develop our ClearCell™ System into a health-care solution that will empower cancer clinicians and researchers to manage cancer in a more effective manner," said Mr Johnson Chen, Founder of Clearbridge BioMedics.

Clearbridge BioMedics is a spin-off company from the Faculty of Engineering, National University of Singapore. Its proprietary ClearCell™ System is able to effectively detect, isolate and retrieve wholly-intact circulating tumour cells from patients' blood samples. This has numerous applications in the areas of cancer

screening, diagnosis and treatment monitoring. The ClearCell™ System has achieved ISO13485 certification, and is available for the cancer research market.

- End -

About Clearbridge BioMedics

Clearbridge BioMedics specializes in novel platforms with applications in oncology research and diagnostics. It is a National University of Singapore (NUS) spinoff company that is committed to developing medical devices, which will impact the world and revolutionize cancer diagnostics and patient care, by leveraging on ground-breaking technology from research partners.

The ClearCell™ System comprises patent-pending CTChips®, which are microfluidic biochips able to effectively detect and isolate wholly-intact CTCs (Circulating Tumor Cells) from small quantities of patient blood samples. The isolated CTCs can then be stained directly on the CTChips® for identification and enumeration, or retrieved for further molecular analysis. The ClearCell™ System aims to be the next generation of non-invasive “liquid biopsy” approach for cancer screening, diagnosis, staging, personalised medication, and treatment monitoring. Headquartered in Singapore, Clearbridge BioMedics currently has customers spanning Asia, Europe and North America. www.clearbridgebiomedics.com

Media enquiries can be directed to:

Chan Yiu Lin (Ms)

Greener Grass Communications

Mobile: (65) 9-765 5897

Email: yiulin@greenergrass.com.sg or media@clearbridgeaccelerator.com